<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>Breast Cancer Prevention | Archangel Michael Health</title>

  <!-- Shared stylesheet -->
  <link rel="stylesheet" href="https://docbraymd.github.io/amh/style_v2.css" />

  <!-- html2pdf for one-click PDF download -->
  <script defer src="https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.10.1/html2pdf.bundle.min.js"></script>

  <style>
    /* Page-local table styling (requested) */
    .amh-table-wrap { overflow-x: auto; }
    table.amh-table {
      width: 100%;
      border-collapse: collapse;
      margin: 14px 0 8px 0;
      font-size: 0.95rem;
      line-height: 1.45;
    }
    table.amh-table th, table.amh-table td {
      border: 1px solid var(--amh-border);
      padding: 10px 10px;
      vertical-align: top;
    }
    table.amh-table th {
      background: var(--amh-bg-soft);
      font-weight: 800;
      text-align: left;
    }
    .amh-table-note {
      font-size: 0.92rem;
      color: var(--amh-text-soft);
      margin-top: 6px;
    }
  
    /* Infographics (click to expand) */
    figure.amh-figure {
      margin: 18px 0;
    }
    img.amh-infographic {
      width: 100%;
      height: auto;
      max-width: 980px;
      display: block;
      margin: 12px auto 6px auto;
      border-radius: 14px;
      box-shadow: 0 10px 24px rgba(0,0,0,0.12);
      cursor: zoom-in;
      border: 1px solid var(--amh-border);
      background: #fff;
    }
    .amh-figcaption {
      text-align: center;
      font-size: 0.92rem;
      color: var(--amh-text-soft);
      margin: 0 auto;
      max-width: 980px;
    }
    body.amh-modal-open {
      overflow: hidden;
    }
    .amh-img-modal {
      position: fixed;
      inset: 0;
      display: none;
      align-items: center;
      justify-content: center;
      padding: 22px;
      background: rgba(0,0,0,0.88);
      z-index: 9999;
    }
    .amh-img-modal.open {
      display: flex;
    }
    .amh-img-modal img {
      max-width: 96vw;
      max-height: 92vh;
      width: auto;
      height: auto;
      border-radius: 14px;
      box-shadow: 0 18px 42px rgba(0,0,0,0.45);
      cursor: zoom-out;
      background: #fff;
    }
    .amh-img-close {
      position: fixed;
      top: 14px;
      right: 14px;
      width: 46px;
      height: 46px;
      border-radius: 999px;
      border: 1px solid rgba(255,255,255,0.25);
      background: rgba(255,255,255,0.12);
      color: #ffffff;
      font-size: 28px;
      line-height: 1;
      cursor: pointer;
    }
    .amh-img-close:focus {
      outline: 3px solid rgba(255,255,255,0.35);
      outline-offset: 2px;
    }

  </style>
</head>

<body>
  <div class="amh-page main-container" id="pdf-root" role="document">
    <header class="amh-header">
      <div class="amh-header-inner amh-header-centered">
        <div class="amh-logo-wrap">
          <img class="amh-logo" src="https://docbraymd.github.io/amh/AMHLogo.png" alt="Archangel Michael Health logo" />
        </div>

        <div class="amh-practice doctor-tag">Archangel Michael Health</div>

        <h1 class="amh-title" id="page-title">Breast Cancer Prevention</h1>
        <h2 class="amh-tagline">Patient Guide: Lifestyle, Integrative &amp; Conventional Prevention</h2>
        <div class="byline">by Christopher L. Bray MD PhD</div>

        <div class="action-bar amh-actions no-print" aria-label="Actions">
          <button class="amh-btn amh-btn-secondary" type="button" onclick="window.print()">
            Print / Save as PDF
          </button>
          <button class="amh-btn amh-btn-primary" id="downloadPdfBtn" type="button">
            Download PDF
          </button>
        </div>
      </div>
    </header>

        <div class="amh-content content-body">
      <p>
        Breast cancer risk is influenced by a mix of non-modifiable factors (age, genetics, breast density, reproductive history)
        and modifiable factors (alcohol, body composition, metabolic health, physical activity, diet quality, smoking, sleep/circadian rhythm,
        environmental exposures, and selected medications/hormones). This guide is designed for the sophisticated patient who wants
        a pragmatic, evidence-informed prevention plan that combines standard preventive care with high-ROI lifestyle and integrative strategies.
      </p>

      <div class="toc no-print" aria-label="On this page">
        <h2>On this page</h2>
        <ul class="amh-list">
          <li><a href="#overview">Overview and key points</a></li>
          <li><a href="#symptoms">Symptoms and red flags</a></li>
          <li><a href="#diagnosis">Risk assessment, screening, and what to test</a></li>
          <li><a href="#drivers">Root causes and contributing factors</a></li>
          <li><a href="#plan">Step-by-step prevention plan</a></li>
          <li><a href="#treatments">Conventional prevention and high-risk management</a></li>
          <li><a href="#integrative">Integrative options</a></li>
          <li><a href="#costs">Cost considerations</a></li>
          <li><a href="#faq">FAQ</a></li>
          <li><a href="#references">References</a></li>
        </ul>
      </div>

      <h3 id="overview">Overview and key points</h3>
      <p>
        Prevention is not “one pill” or “one test.” It is risk stratification plus long-term behavior and environment design.
        A practical approach is to (1) quantify baseline risk, (2) optimize the “big levers” that meaningfully shift biology
        (alcohol, adiposity/insulin, activity, diet quality, smoking, sleep/circadian alignment), (3) reduce endocrine-disrupting and carcinogenic exposures,
        and (4) choose screening and medical prevention strategies that match risk level and preferences.
      </p>

      <div class="clinical-note">
        <strong>Clinical note:</strong> Breast cancer is heterogeneous. “Estrogen receptor positive” (ER+) cancers are most common and are influenced by lifetime estrogen exposure,
        adiposity/insulin signaling, inflammation, and (likely) endocrine-disrupting chemical exposures. Prevention strategies often target those upstream drivers.
      </div>

      <div class="success-box">
        <strong>High-yield summary:</strong>
        <ul class="amh-list">
          <li><strong>Alcohol:</strong> dose-dependent increase in risk; for breast cancer, “less is better.”</li>
          <li><strong>Body fat and insulin resistance:</strong> major, modifiable, high-ROI driver of post-menopausal risk.</li>
          <li><strong>Exercise:</strong> consistently associated with lower risk and lower recurrence risk in survivors.</li>
          <li><strong>Diet quality:</strong> emphasize plant-forward, high-fiber, minimally processed patterns; limit ultra-processed foods.</li>
          <li><strong>Sleep/circadian rhythm:</strong> prioritize adequate sleep and avoid long-term night shift work when possible.</li>
          <li><strong>EDC avoidance:</strong> reduce routine exposures that can act as xenoestrogens or disrupt hormone signaling.</li>
          <li><strong>Risk-based screening:</strong> mammography saves lives but also causes false positives and some overdiagnosis; tailor decisions to risk, breast density, and life expectancy.</li>
          <li><strong>Very high risk:</strong> consider MRI screening, chemoprevention, and (in select cases) risk-reducing surgery.</li>
        </ul>
      </div>


      <figure class="amh-figure" aria-label="Lifestyle prevention summary infographic">
        <img
          class="amh-infographic"
          src="https://docbraymd.github.io/amh/breastca_lifestyle.jpg"
          alt="Infographic summarizing high-yield lifestyle features that can reduce breast cancer risk."
          loading="lazy"
          decoding="async"
        />
        <figcaption class="amh-figcaption">Lifestyle prevention summary (click the image to enlarge).</figcaption>
      </figure>



      <h3 id="symptoms">Symptoms and red flags</h3>
      <p>
        This page focuses on prevention, but knowing warning signs matters. Many breast cancers are detected on screening before symptoms occur.
        If you notice new or concerning changes, seek clinical evaluation promptly rather than “watching it for months.”
      </p>

      <div class="alert-box">
        <strong>Red flags (seek prompt evaluation):</strong>
        <ul class="amh-list">
          <li>New palpable lump or firm thickening that persists beyond a menstrual cycle.</li>
          <li>New nipple inversion, spontaneous nipple discharge (especially bloody), or persistent scaling/eczema of the nipple/areola.</li>
          <li>Skin dimpling, peau d’orange texture, or focal swelling/redness not explained by infection.</li>
          <li>Rapid change in breast size/shape, or new persistent focal pain (especially if associated with a mass).</li>
          <li>Enlarged axillary or supraclavicular lymph nodes without another clear cause.</li>
        </ul>
      </div>

      <h4>Self breast exam and “breast awareness”</h4>
      <p>
        Formal monthly self-breast examination has not shown a mortality benefit in large trials and can increase false alarms and benign biopsies.
        However, “breast awareness” is reasonable: know your baseline and pay attention to new, persistent changes. If you prefer a structured self-exam,
        ask your clinician to teach a technique designed to minimize unnecessary alarm.
      </p>

      <h4>Clinical breast exam</h4>
      <p>
        Clinical breast exam (performed by a clinician) is sometimes included during routine preventive visits. For average-risk patients, evidence that it
        adds substantial benefit on top of modern mammography is limited, and recommendations vary. In practice, it can be helpful when symptoms are present,
        for people who are not up-to-date on screening, or in settings where imaging access is limited.
      </p>

      <h3 id="diagnosis">Risk assessment, screening, and what to test</h3>
      <p>
        The goal of “diagnosis” in prevention is to identify your risk tier and match that with an appropriate screening and prevention strategy.
        Two people the same age can have very different risk profiles based on family history, breast density, reproductive exposures, prior biopsies,
        and genetic variants.
      </p>

      <h4>Risk calculators</h4>
      <p>
        Risk calculators estimate short-term (5–10 year) and/or lifetime risk. They differ in what they include, so results can vary.
        These tools are most useful to decide whether you meet thresholds for enhanced screening (e.g., MRI) or chemoprevention.
      </p>
      <ul class="amh-list symptom-list">
        <li><strong><a href="https://bcrisktool.cancer.gov/" target="_blank" rel="noopener">NCI Breast Cancer Risk Assessment Tool (Gail model)</a>:</strong> widely used; includes age, reproductive factors, limited family history, and prior biopsies.</li>
        <li><strong><a href="https://tools.bcsc-scc.ucdavis.edu/BC5yearRisk/" target="_blank" rel="noopener">BCSC Risk Calculator</a>:</strong> incorporates breast density and prior biopsy information; useful for screening decisions.</li>
        <li><strong><a href="https://canrisk.org/" target="_blank" rel="noopener">CanRisk (BOADICEA / Tyrer–Cuzick family-history-based tools)</a>:</strong> more detailed family history and genetic components; commonly used in high-risk clinics.</li>
        <li><strong><a href="https://magview.com/ibis-risk-calculator/" target="_blank" rel="noopener">Tyrer–Cuzick (IBIS) interface information</a>:</strong> often used to estimate lifetime risk and guide MRI eligibility (availability varies by clinic/software).</li>
      </ul>

      <div class="clinical-note">
        <strong>Practical thresholds used in many clinics:</strong> A lifetime risk ≥20% (by certain models) often triggers consideration of annual breast MRI in addition to mammography.
        A 5-year risk ≥1.7% (Gail) has historically been used as a threshold to discuss chemoprevention, but decision-making should be individualized.
      </div>

      <h4>Breast density: why it matters</h4>
      <p>
        Breast density is both (1) an independent risk factor and (2) a factor that reduces mammography sensitivity (dense tissue can mask tumors).
        Density is usually reported as: almost entirely fatty, scattered fibroglandular densities, heterogeneously dense, or extremely dense.
        Dense breasts are common and are not “abnormal,” but they can change screening strategy.
      </p>
      <p>
        Dense breasts are associated with higher false-positive recalls and can increase the chance that an interval cancer is diagnosed between screens.
        Modern 3D mammography (tomosynthesis) can modestly reduce recalls compared with 2D mammography for many women, although benefits vary by density.
      </p>

      <h4>Screening options (average and increased risk)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Mammography (2D or 3D/tomosynthesis):</strong> the core population screening tool; most evidence for mortality benefit.</li>
        <li><strong>Breast MRI:</strong> highest sensitivity; typically reserved for high-risk individuals (e.g., genetic risk, very high lifetime risk, prior chest radiation).</li>
        <li><strong>Breast ultrasound:</strong> sometimes used as supplemental screening in dense breasts; increases detection but also increases false positives.</li>
        <li><strong>Contrast-enhanced mammography:</strong> emerging option in some centers for certain risk profiles when MRI is not feasible.</li>
      </ul>

      <h4>Thermography (important clarification)</h4>
      <p>
        Thermography is not an approved substitute for mammography. It may detect heat patterns, but it has not demonstrated the reliability needed to replace imaging
        that directly visualizes tissue changes. If thermography is used at all, it should only be considered an adjunct and should never delay indicated mammography or diagnostic imaging.
      </p>

      <h4>When to stop screening: life expectancy and individualized decisions</h4>
      <p>
        For older adults, the main issue is not “age alone,” but whether you are likely to live long enough to benefit from screening (benefits accrue over years),
        versus experiencing harms (false positives, overdiagnosis, procedures) sooner. I often use the ePrognosis tool to support shared decision-making:
        <a href="https://eprognosis.ucsf.edu/cancer/partials/breast-cancer.php" target="_blank" rel="noopener">ePrognosis Breast Cancer Screening Decision Tool</a>.
      </p>

      <h3 id="drivers">Root causes and contributing factors</h3>
      <p>
        Some risk factors are not modifiable (age, certain gene variants, prior chest radiation, strong family history). Many others are modifiable and are the primary focus here.
        Think in terms of upstream biology: estrogen exposure and signaling, insulin/IGF-1 signaling, inflammation, oxidative stress, immune surveillance, and environmental endocrine disruption.
      </p>

      <h4>Non-modifiable or partly modifiable factors</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Age:</strong> risk rises with age.</li>
        <li><strong>Genetics and family history:</strong> BRCA1/2 and other genes; early diagnoses or multiple affected relatives increases risk.</li>
        <li><strong>Breast density:</strong> independent risk factor and reduces screening sensitivity.</li>
        <li><strong>Reproductive history:</strong> early menarche, later menopause, later age at first full-term pregnancy, and fewer pregnancies slightly increase lifetime exposure to estrogen.</li>
        <li><strong>Prior biopsies:</strong> atypical ductal hyperplasia, atypical lobular hyperplasia, and LCIS increase future risk.</li>
      </ul>

      <h4>Alcohol</h4>
      <p>
        Alcohol is one of the most consistent and modifiable breast cancer risk factors. Mechanisms include increased estrogen levels, acetaldehyde exposure,
        oxidative stress, and impaired folate metabolism. From a prevention standpoint, the key message is dose-response: fewer drinks per week is better.
        If you drink, consider lowering frequency, choosing smaller servings, and building alcohol-free default routines.
      </p>

      <h4>Smoking and secondhand smoke</h4>
      <p>
        Smoking is associated with increased breast cancer risk and worsened overall cancer outcomes, and it amplifies oxidative stress and inflammation.
        Smoking cessation has broad benefits and remains a core prevention target.
      </p>

      <h4>Obesity, insulin resistance, and inflammation</h4>
      <p>
        Adipose tissue is hormonally active: it increases aromatase activity (conversion of androgens to estrogen), raises insulin/IGF-1 signaling,
        and increases inflammatory cytokines. Post-menopausal ER+ breast cancer risk is strongly linked to adiposity and metabolic dysfunction.
        Prevention is not about “thinness”; it is about metabolic health, lean mass, insulin sensitivity, and reducing visceral fat.
      </p>

      <h4>Physical activity and exercise</h4>
      <p>
        Exercise improves insulin sensitivity, reduces inflammation, improves immune surveillance, and helps regulate estrogen metabolism and body composition.
        Practical targets:
      </p>
      <ul class="amh-list symptom-list">
        <li><strong>Baseline:</strong> 150–300 minutes/week of moderate activity or 75–150 minutes/week vigorous activity, plus 2+ days/week of resistance training.</li>
        <li><strong>High ROI:</strong> brisk walking, cycling, swimming, and strength training focused on major muscle groups.</li>
        <li><strong>Reduce sedentary time:</strong> frequent movement breaks matter, especially for desk-based work.</li>
      </ul>

      <h4>Sleep, circadian rhythm, and night shift work</h4>
      <p>
        Circadian disruption can alter melatonin signaling, immune function, glucose regulation, and estrogen pathways. Long-term night shift work has been associated
        with a modestly increased breast cancer risk in multiple studies, with higher risk often reported with longer duration or more intense patterns of night work.
        If night shift work is unavoidable, mitigation strategies include consistent sleep timing on off-days when possible, strong morning light exposure after waking,
        minimizing bright light exposure at night, and prioritizing sleep quality.
      </p>

      <h4>Estrogen exposure: hormonal contraception and hormone replacement therapy</h4>
      <p>
        Breast cancer risk is influenced by cumulative lifetime estrogen exposure, but the relationship is nuanced.
        <strong>Combined hormonal contraception</strong> (estrogen + progestin) is associated with a small increase in breast cancer risk during use and for some time after discontinuation,
        with the absolute risk remaining low for most younger women. Decisions should incorporate the strong benefits of contraception and cycle control.
      </p>
      <p>
        <strong>Menopausal hormone therapy (HRT):</strong> the type of progestogen matters. The best randomized trial data that showed increased breast cancer risk used a synthetic progestin
        (medroxyprogesterone acetate) combined with estrogen. Observational data suggest that <strong>micronized (natural) progesterone</strong> may have a lower breast cancer risk profile
        than certain synthetic progestins, but it is not “risk-free,” and longer duration and higher cumulative exposure still matter. For patients who need HRT for quality of life,
        discuss lowest effective dose, shortest necessary duration, non-hormonal options, and the choice of transdermal estrogen and progesterone formulations.
      </p>

      <h4>Estrogen metabolism: higher-risk vs lower-risk pathways</h4>
      <p>
        Estrogens are metabolized through several pathways. In simplified terms, some metabolites are considered more proliferative or potentially DNA-damaging,
        while others are considered less biologically aggressive. The major pathways involve hydroxylation (Phase I) and then methylation/conjugation (Phase II).
      </p>
      <ul class="amh-list symptom-list">
        <li><strong>2-hydroxylation (“2-OH” pathway):</strong> often described as a lower-risk pathway; metabolites are generally less estrogenic.</li>
        <li><strong>4-hydroxylation (“4-OH” pathway):</strong> can form reactive quinones that may damage DNA if not adequately detoxified.</li>
        <li><strong>16α-hydroxylation (“16-OH” pathway):</strong> associated with more proliferative signaling in some research contexts.</li>
      </ul>
      <p>
        A practical prevention approach is to support the body’s ability to handle estrogen through diet, microbiome support, and methylation capacity,
        rather than pursuing aggressive “detox” claims. High-ROI steps include: a high-fiber diet (supports estrogen excretion), regular bowel movements,
        cruciferous vegetables (broccoli, cabbage, Brussels sprouts), adequate protein and micronutrients for Phase II pathways, and avoidance of alcohol excess.
        Some integrative practices use urine estrogen metabolite testing, but clinical outcome data are limited; interpret results cautiously and focus on foundations first.
      </p>

      <figure class="amh-figure" aria-label="Estrogen metabolism infographic">
        <img
          class="amh-infographic"
          src="https://docbraymd.github.io/amh/breastca_estrogens.jpg"
          alt="Infographic explaining major pathways of estrogen metabolism and downstream metabolites."
          loading="lazy"
          decoding="async"
        />
        <figcaption class="amh-figcaption">Estrogen metabolism overview (click the image to enlarge).</figcaption>
      </figure>


      <h4>Environmental endocrine disruptors and breast cancer risk</h4>
      <p>
        Many modern chemicals can act as endocrine-disrupting chemicals (EDCs), including some that mimic estrogen (xenoestrogens) or interfere with hormone receptors,
        metabolism, and signaling. Evidence quality varies by chemical; the prevention philosophy is “reduce routine, high-frequency exposure where feasible.”
      </p>

      <div class="success-box">
        <strong>High-ROI EDC avoidance strategies (practical):</strong>
        <ul class="amh-list">
          <li><strong>Food and storage:</strong> avoid heating food in plastic; use glass/stainless; reduce canned foods when possible.</li>
          <li><strong>Personal care:</strong> choose fragrance-free or low-chemical products; limit parabens/phthalates; simplify routines.</li>
          <li><strong>Receipts:</strong> minimize handling thermal paper receipts; wash hands after exposure.</li>
          <li><strong>Water:</strong> consider filtration (especially where PFAS concerns exist); use a quality filter matched to local water reports.</li>
          <li><strong>Cookware:</strong> reduce exposure to damaged non-stick coatings; consider stainless, cast iron, or safer ceramic options.</li>
          <li><strong>Home dust:</strong> wet-dust and HEPA vacuuming can reduce flame retardant and phthalate exposure in indoor dust.</li>
        </ul>
      </div>

            <h4>Makeup, perfumes, and personal care products</h4>
      <p>
        Personal care products can be a meaningful source of repeated, long-term exposure to endocrine-disrupting and sensitizing chemicals.
        The epidemiology linking specific products to breast cancer risk is not always consistent, but several exposure classes are biologically plausible
        because they can influence estrogen signaling, hormone metabolism, or chronic inflammation. For prevention-minded patients, the practical goal is not perfection;
        it is reducing routine, high-frequency exposures—especially to “fragrance” mixtures and certain preservative/plasticizer classes.
      </p>
      <p>
        Common exposure classes discussed in the prevention literature include <strong>fragrance-related phthalates</strong> (often present when “fragrance/parfum” is listed),
        certain <strong>paraben preservatives</strong>, some <strong>UV filters</strong> used in cosmetics, and <strong>PFAS</strong> (“forever chemicals”) that have been identified
        in some long-wear and water-resistant products. In addition, occasional contamination with <strong>heavy metals</strong> has been reported in certain cosmetic products.
        While individual product effects are usually small, the cumulative exposure profile can be meaningful over decades.
      </p>

      <div class="success-box">
        <strong>Practical risk-reduction steps (high ROI):</strong>
        <ul class="amh-list">
          <li><strong>Default to fragrance-free:</strong> prioritize “fragrance-free” over “unscented” (which can still contain masking fragrances).</li>
          <li><strong>Simplify the routine:</strong> fewer products used daily generally means lower cumulative exposure.</li>
          <li><strong>Read labels:</strong> avoid products listing “fragrance/parfum” as a default; consider reducing parabens and phthalates when feasible.</li>
          <li><strong>Aerosols and sprays:</strong> minimize inhalation exposure from hair sprays, perfumes, and powdered cosmetics; apply in well-ventilated areas.</li>
          <li><strong>Long-wear products:</strong> consider limiting “long-wear/waterproof” items if you are trying to reduce PFAS exposure.</li>
          <li><strong>Hands and lips:</strong> be selective with products used on lips and hands (higher ingestion/dermal contact over time).</li>
          <li><strong>Pregnancy and puberty:</strong> these are sensitive windows; consider a more stringent “low-chemical” approach during these periods.</li>
        </ul>
      </div>
<h4>Aluminum antiperspirants (what we know)</h4>
      <p>
        Aluminum-containing antiperspirants are sometimes discussed online as a breast cancer risk. The strongest available evidence does not support a clear causal link.
        However, personal care products can be sources of fragrance chemicals, parabens, and other compounds that may have endocrine activity. If you prefer to reduce exposure,
        you can choose aluminum-free, fragrance-free products as a low-risk, optional precaution without assuming it is a proven breast cancer prevention strategy.
      </p>

      <h4>Breastfeeding</h4>
      <p>
        Breastfeeding is associated with reduced breast cancer risk, particularly with longer cumulative duration. The mechanisms likely include hormonal changes,
        reduced lifetime menstrual cycles, and differentiation of breast tissue. This is not a “requirement” for prevention, but it is a measurable protective factor.
      </p>

      <h4>Sauna and heat exposure</h4>
      <p>
        Sauna use is associated in observational studies with cardiometabolic benefits and may improve insulin sensitivity and inflammation—upstream drivers relevant to cancer biology.
        Direct evidence that sauna prevents breast cancer is limited. If used, treat sauna as an adjunct to (not a substitute for) the foundational lifestyle levers.
        Avoid dehydration, use caution with low blood pressure, pregnancy, or unstable cardiac conditions, and build gradually.
      </p>

      <h4>Fasting and time-restricted eating</h4>
      <p>
        Intermittent fasting and time-restricted eating can help some individuals reduce energy intake, improve insulin sensitivity, and support weight loss—pathways relevant to post-menopausal risk.
        Evidence for fasting as a direct breast cancer prevention tool is still evolving. If you use fasting, keep it sustainable, avoid under-protein intake, and avoid extreme approaches
        that worsen sleep, stress, or relationship with food.
      </p>

      <h3 id="plan">Step-by-step prevention plan</h3>
      <div class="success-box">
        <strong>Practical plan:</strong> focus on the “big levers,” then refine. For most patients, durable risk reduction comes from months-to-years of consistent behavior rather than intense short bursts.
      </div>

      <h4>Step 1: Stratify your baseline risk</h4>
      <ul class="amh-list symptom-list">
        <li>Document family history (first- and second-degree relatives; ages at diagnosis).</li>
        <li>Confirm breast density from your mammography report.</li>
        <li>Use a risk calculator (see above) and discuss results with your clinician.</li>
        <li>Consider genetics referral if family history is strong or suggests hereditary risk.</li>
      </ul>

      <h4>Step 2: Alcohol strategy (high ROI)</h4>
      <ul class="amh-list symptom-list">
        <li>If you drink: set a weekly cap and schedule alcohol-free days by default.</li>
        <li>Prefer smaller servings; avoid using alcohol as stress management.</li>
        <li>Pair alcohol reduction with sleep improvement and stress skills so it is sustainable.</li>
      </ul>

      <h4>Step 3: Body composition and insulin strategy</h4>
      <ul class="amh-list symptom-list">
        <li>Target waist circumference and visceral fat reduction through diet quality, resistance training, and daily movement.</li>
        <li>Prioritize protein adequacy, fiber, and minimally processed carbohydrates; reduce ultra-processed foods and sugar-sweetened beverages.</li>
        <li>If indicated: evaluate A1c, fasting insulin, triglycerides/HDL ratio, and blood pressure as markers of metabolic health.</li>
      </ul>

      <h4>Step 4: Exercise “minimum effective dose”</h4>
      <ul class="amh-list symptom-list">
        <li>Build a weekly routine: 3–5 days of moderate activity + 2–3 days resistance training.</li>
        <li>Include at least one session that challenges you (intervals or hills) if safe for your joints and cardiovascular status.</li>
        <li>Track consistency, not perfection.</li>
      </ul>

      <h4>Step 5: Diet pattern (plant-forward, high fiber, low ultra-processed)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Foundation:</strong> vegetables, legumes, fruit, whole grains, nuts/seeds, and quality proteins.</li>
        <li><strong>Fiber target:</strong> many adults benefit from 25–40 g/day (increase gradually; hydrate).</li>
        <li><strong>Key foods:</strong> cruciferous vegetables, berries, mushrooms, ground flaxseed, and fatty fish (or algae-based omega-3).</li>
        <li><strong>Soy:</strong> whole-food soy (tofu, edamame, tempeh) is generally considered safe and may be protective; avoid fear-based myths.</li>
      </ul>

      <h4>Step 6: Sleep and circadian alignment</h4>
      <ul class="amh-list symptom-list">
        <li>Protect a stable sleep window (7–9 hours for most adults).</li>
        <li>Bright light exposure shortly after waking; dim light in the evening.</li>
        <li>If you do night shift work: prioritize a consistent sleep schedule and discuss mitigation strategies with your clinician.</li>
      </ul>

      <h4>Step 7: Reduce endocrine-disrupting exposures</h4>
      <p>
        Choose a few high-ROI changes rather than attempting “perfect purity.” Your goal is to reduce chronic, high-frequency exposures.
      </p>

      <h4>Step 8: Choose a screening strategy aligned with risk and preferences</h4>
      <p>
        Screening can reduce breast cancer mortality, but it also generates false-positive recalls, biopsies, anxiety, and overdiagnosis. The tradeoffs are not identical across age and density.
      </p>

            <div class="amh-table-wrap">
        <table class="amh-table" aria-label="Breast cancer screening outcomes by age range">
          <thead>
            <tr>
              <th>Age range (biennial screening)</th>
              <th>Deaths averted<br><span style="font-weight:400;">per 1,000 women</span></th>
              <th>False-positive recalls<br><span style="font-weight:400;">per 1,000 women</span></th>
              <th>Overdiagnosed cases<br><span style="font-weight:400;">per 1,000 women</span></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>40–49 years</strong></td>
              <td>1.5</td>
              <td>492</td>
              <td>2</td>
            </tr>
            <tr>
              <td><strong>50–59 years</strong></td>
              <td>3.0</td>
              <td>392</td>
              <td>6</td>
            </tr>
            <tr>
              <td><strong>60–74 years</strong></td>
              <td>3.7</td>
              <td>492</td>
              <td>6</td>
            </tr>
            <tr>
              <td><strong>75–79 years</strong></td>
              <td>0.8</td>
              <td>Not separately reported</td>
              <td>Not separately reported</td>
            </tr>
          </tbody>
        </table>
        <div class="amh-table-note">
          These decade/age-range estimates are intended to support shared decision-making about when to start and when to stop screening.
          They are based on the 2024 USPSTF collaborative modeling analysis and the 2024 USPSTF recommendation statement (see References).
          Estimates assume 100% screening adherence with digital breast tomosynthesis (DBT) and reflect modeled lifetime outcomes.
        </div>
        <div class="amh-table-note">
          Practical interpretation: Starting biennial screening at age 40 (vs 50) adds an estimated 1.5 additional deaths averted per 1,000 women, at the cost of many more false-positive recalls in the 40s.
          Extending screening from age 74 to 79 adds an estimated 0.8 additional deaths averted per 1,000 women; decisions in the late 70s should be strongly guided by overall health, competing risks, and life expectancy.
        </div>
      </div>

      <h4>Harms of false positives (often underappreciated)</h4>
      <p>
        False-positive recalls are not “free.” They can cause substantial short-term anxiety, weeks of uncertainty, time away from work, and direct out-of-pocket costs.
        Biopsies can be painful, can cause bruising and hematoma, and some people experience persistent discomfort or tenderness at the biopsy site.
        Some patients also report longer-lasting anxiety around future screening. These harms matter in shared decision-making.
      </p>

      <h3 id="treatments">Conventional prevention and high-risk management</h3>
      <p>
        “Conventional prevention” includes risk-based screening and, for selected higher-risk patients, medications (chemoprevention) or risk-reducing surgery.
        The highest-risk individuals benefit most from aggressive strategies.
      </p>

      <h4>Standard screening (average risk)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>USPSTF:</strong> biennial mammography for ages 40–74 (average risk), with individualized decisions beyond that range.</li>
        <li><strong>Breast density:</strong> dense breasts may justify discussion of tomosynthesis and supplemental imaging depending on risk and local resources.</li>
      </ul>

      <h4>High-risk screening (examples)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Annual MRI + mammography:</strong> often used when lifetime risk is ≥20% or for known high-risk gene carriers.</li>
        <li><strong>Earlier and more intensive strategies:</strong> may be indicated for those with prior chest radiation at a young age or strong hereditary risk patterns.</li>
      </ul>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Breast MRI (high-risk screening)</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>Contrast-enhanced MRI is the most sensitive screening modality and can detect cancers missed by mammography, especially in dense breasts.</div>

          <div class="rx-label">How it works</div>
          <div>Uses magnetic fields and intravenous contrast to highlight vascular patterns often present in malignancy.</div>

          <div class="rx-label">Typical use</div>
          <div>Usually annual for high-risk patients, typically in addition to (not instead of) mammography; requires shared decision-making about false positives.</div>

          <div class="rx-label">Side effects</div>
          <div>Contrast reactions are uncommon; claustrophobia and incidental findings occur; false positives are more common than mammography.</div>

          <div class="rx-label">Cost</div>
          <div>Often higher out-of-pocket costs if not covered; prices vary widely by region and facility.</div>
        </div>
      </div>

      <h4>Medication prevention (chemoprevention): who should consider it?</h4>
      <p>
        For patients at higher-than-average risk (based on risk calculators, prior atypia/LCIS, or strong family history),
        anti-estrogen medications can lower the risk of developing ER+ breast cancer. These medications are not used for everyone; the decision depends on risk level and tolerance for side effects.
      </p>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Selective estrogen receptor modulators (SERMs): Tamoxifen / Raloxifene</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>Medications that block estrogen signaling in breast tissue; used for prevention in selected higher-risk individuals.</div>

          <div class="rx-label">How it works</div>
          <div>Antagonizes estrogen receptors in breast tissue, reducing estrogen-driven proliferation (most benefit is for ER+ risk reduction).</div>

          <div class="rx-label">Typical use</div>
          <div>Often a 5-year course in appropriate candidates; selection depends on menopausal status and risk/benefit profile.</div>

          <div class="rx-label">Side effects</div>
          <div>Hot flashes, vaginal symptoms; tamoxifen can increase venous thromboembolism risk and (rarely) endometrial cancer risk; raloxifene has lower uterine risk and is used in post-menopausal patients.</div>

          <div class="rx-label">Cost</div>
          <div>Generics are often affordable; costs vary by pharmacy and insurance status.</div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Aromatase inhibitors (AIs): Anastrozole / Exemestane</div>
          <div class="rx-type">STANDARD</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">What it is</div>
          <div>Medications used in post-menopausal patients to lower estrogen production; used for prevention in selected high-risk individuals.</div>

          <div class="rx-label">How it works</div>
          <div>Inhibits aromatase, the enzyme that converts androgens to estrogen in adipose tissue and other tissues, lowering systemic estrogen levels.</div>

          <div class="rx-label">Typical use</div>
          <div>Typically a multi-year course (often 5 years) in post-menopausal candidates with elevated risk; monitor symptoms and bone health.</div>

          <div class="rx-label">Side effects</div>
          <div>Joint/muscle aches, hot flashes, vaginal dryness; can accelerate bone loss—bone density monitoring and bone-protective strategies are important.</div>

          <div class="rx-label">Cost</div>
          <div>Often available as generics; out-of-pocket ranges vary.</div>
        </div>
      </div>

      <h4>Risk-reducing surgery for very high risk</h4>
      <p>
        For certain very high-risk individuals (e.g., high-risk pathogenic gene variants or extremely strong family history),
        risk-reducing bilateral mastectomy can dramatically lower breast cancer incidence. This is a major decision with physical and psychological implications
        and should be guided by a high-risk clinic and shared decision-making. Risk-reducing salpingo-oophorectomy is relevant for ovarian cancer prevention in certain gene carriers
        and can also influence breast cancer risk depending on timing.
      </p>

      <h3 id="integrative">Integrative options</h3>
      <p>
        Integrative approaches can complement (not replace) standard screening and risk-based medical management.
        Focus on realistic, safe strategies with plausible mechanisms and some supportive evidence.
      </p>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Vitamin D (optimize, don’t megadose)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>Vitamin D status is associated with multiple health outcomes; some observational data suggest an association between adequate vitamin D and improved breast cancer outcomes, but prevention causality is not definitive.</div>

          <div class="rx-label">Typical use</div>
          <div>Common approach is to measure 25(OH)D and supplement if low; target ranges vary by clinician. Recheck after 8–12 weeks if making a major dose change.</div>

          <div class="rx-label">Safety</div>
          <div>Excess dosing can cause hypercalcemia; use caution with kidney stones or granulomatous disease; consider magnesium adequacy.</div>

          <div class="rx-label">Cost</div>
          <div>Usually low; typical over-the-counter pricing.</div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Melatonin (circadian support; possible oncostatic properties)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>Melatonin is a circadian hormone with antioxidant and immune-modulating properties. Circadian disruption is linked to cancer biology in experimental models, and melatonin has been studied as an adjunct in some oncology settings. Direct evidence for melatonin as a primary prevention supplement is limited.</div>

          <div class="rx-label">Typical use</div>
          <div>Often used for sleep timing support: low doses (e.g., 0.3–1 mg) may help circadian alignment; higher doses (e.g., 2–5 mg) are sometimes used for insomnia. Timing matters—typically 1–2 hours before desired sleep.</div>

          <div class="rx-label">Safety</div>
          <div>Possible vivid dreams, morning grogginess, headaches; use caution if driving early morning. Discuss use in pregnancy, seizure disorders, severe depression, or if on immunosuppressive therapy.</div>

          <div class="rx-label">Cost</div>
          <div>Generally inexpensive; varies by brand and formulation.</div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Cruciferous phytochemicals (food-first; DIM / sulforaphane as optional)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>Cruciferous vegetables contain compounds that can influence Phase I/II detoxification enzymes and estrogen metabolism (food-first approach). Supplements like DIM or sulforaphane extracts may be considered in select cases, but outcome data are limited.</div>

          <div class="rx-label">Typical use</div>
          <div>Food-first: several servings per week (broccoli, Brussels sprouts, cabbage, kale). If using supplements, start low and assess tolerance.</div>

          <div class="rx-label">Safety</div>
          <div>GI upset in some; use caution with thyroid disease if intake is extreme and iodine intake is low; discuss with clinician if pregnant or on multiple medications.</div>

          <div class="rx-label">Cost</div>
          <div>Food costs vary; supplements are moderate in cost depending on formulation.</div>
        </div>
      </div>

      <div class="rx-card amh-rx-card">
        <div class="rx-header">
          <div class="rx-name">Omega-3 fatty acids (fish or algae)</div>
          <div class="rx-type">INTEGRATIVE</div>
        </div>
        <div class="rx-grid">
          <div class="rx-label">Rationale</div>
          <div>Omega-3s can reduce inflammation and may support cardiometabolic health; evidence for direct breast cancer prevention is mixed, but the metabolic and inflammatory benefits can support an overall prevention strategy.</div>

          <div class="rx-label">Typical use</div>
          <div>Diet-first: fatty fish 1–2 times/week or algae-based omega-3 for plant-forward diets. Supplements vary widely in EPA/DHA content.</div>

          <div class="rx-label">Safety</div>
          <div>Fishy aftertaste; may increase bruising/bleeding risk at higher doses in combination with anticoagulants—discuss if on blood thinners.</div>

          <div class="rx-label">Cost</div>
          <div>Moderate; depends on purity testing and dose.</div>
        </div>
      </div>

      <h4>Foods and spices with plausible benefit (food-first)</h4>
      <ul class="amh-list symptom-list">
        <li><strong>Ground flaxseed:</strong> lignans and fiber; supports estrogen excretion and cardiometabolic health.</li>
        <li><strong>Mushrooms:</strong> immune-active compounds; observational data suggest potential benefit, but causal proof is limited.</li>
        <li><strong>Green tea:</strong> polyphenols (EGCG); modest evidence signals, but avoid overpromising.</li>
        <li><strong>Turmeric/curcumin:</strong> anti-inflammatory signaling; bioavailability varies; food use is safe for most.</li>
        <li><strong>Berries and colorful plants:</strong> polyphenols and fiber; consistent health benefits.</li>
      </ul>

      <h3 id="costs">Cost considerations</h3>
      <ul class="amh-list symptom-list">
        <li><strong>Highest ROI is often free or low-cost:</strong> alcohol reduction, walking, resistance training with minimal equipment, improved sleep routines, and food quality upgrades.</li>
        <li><strong>Screening costs vary:</strong> mammography is often covered as preventive care; MRI and supplemental imaging can generate significant out-of-pocket costs depending on coverage.</li>
        <li><strong>Testing should change management:</strong> prioritize tests that alter screening or prevention decisions (e.g., genetics in high-risk scenarios).</li>
        <li><strong>Supplements:</strong> avoid stacking many products; prefer a small, targeted set with a clear reason and a stop/reassess plan.</li>
      </ul>

      <h3 id="faq">FAQ</h3>
      <h4>Do deodorants or antiperspirants cause breast cancer?</h4>
      <p>
        Current evidence does not support a clear causal link between aluminum-containing antiperspirants and breast cancer.
        If you want to lower overall chemical exposure, aluminum-free and fragrance-free options are reasonable, low-risk choices—but they should not replace the high-impact prevention steps.
      </p>

      <h4>Is thermography a good alternative to mammography?</h4>
      <p>
        No. Thermography should not be used as a replacement for mammography. If used at all, it should only be an adjunct and should never delay appropriate imaging.
      </p>

      <h4>Should everyone take supplements like DIM, turmeric, or melatonin for prevention?</h4>
      <p>
        No supplement is proven to prevent breast cancer in the way vaccines prevent certain infections. Supplements can be adjuncts for selected individuals, but the foundations
        (alcohol, metabolic health, exercise, diet quality, sleep/circadian alignment, and exposure reduction) provide the largest and most reliable risk shift.
      </p>

      <h4>How do I decide when to stop screening?</h4>
      <p>
        If you are older, the key question is whether you are likely to live long enough to benefit from detecting a slow-growing cancer early, versus being more likely to experience harms sooner.
        Use shared decision-making; the ePrognosis tool can help frame that decision in a structured way.
      </p>

            <h4>Is there a “safe” amount of alcohol for breast cancer prevention?</h4>
      <p>
        From a strict prevention perspective, the lowest-risk choice is to avoid alcohol. If you drink, reducing frequency and dose meaningfully improves risk exposure.
        Alcohol also affects sleep quality, blood pressure, arrhythmias, mood, and liver health—so the benefits of reduction often extend beyond cancer risk.
      </p>

      <h4>Do dense breasts automatically mean I need MRI?</h4>
      <p>
        Not automatically. Dense breasts increase risk and reduce mammography sensitivity, but the next step depends on your total risk profile (family history, genetics, prior biopsies, and calculated risk).
        Many patients do well with 3D tomosynthesis; others benefit from supplemental ultrasound or MRI when overall risk is high enough to justify the tradeoff of more false positives.
      </p>

      <h4>Should I take a “breast cancer prevention supplement stack”?</h4>
      <p>
        Usually no. Food-based patterns have the best safety profile and the broadest metabolic and inflammatory benefits.
        If supplements are used, choose a small number with a clear rationale and safety plan—and do not use supplements as a substitute for alcohol reduction, exercise, and weight/metabolic health.
      </p>

      <h4>If I am high risk, should I get a prophylactic mastectomy?</h4>
      <p>
        This is a deeply personal decision. For very high-risk mutation carriers, surgery can offer the largest risk reduction, but it carries major physical and psychosocial tradeoffs.
        Many high-risk patients choose enhanced screening and/or medication prevention instead. A multidisciplinary discussion is essential.
      </p>

      <h4>What is overdiagnosis, and why does it matter?</h4>
      <p>
        Overdiagnosis means finding a cancer through screening that would not have harmed you during your lifetime. Once discovered, it is typically treated—exposing a patient to surgery,
        radiation, and/or medications that do not improve longevity. Overdiagnosis risk increases with age and comorbidity, which is a major reason screening decisions after age 70 should be individualized.
      </p>

      <h4>Does “clean eating” eliminate breast cancer risk?</h4>
      <p>
        No. Lifestyle can meaningfully lower risk, but it cannot reduce risk to zero. Genetics, age, and chance still matter.
        The goal is risk reduction and earlier detection when appropriate—not the promise of a guarantee.
      </p>

      <h4>Which single supplement prevents breast cancer best?</h4>
      <p>
        There is no single supplement with strong evidence to prevent breast cancer across the population.
        If you use supplements, use them to support fundamentals (sleep, metabolic health, and nutrient repletion) rather than as a substitute for them.
      </p>
<h3 id="references">References</h3>
<ol class="ref-list">
                <li>Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. <em>JAMA</em>. 2024;331(22):1947-1960. doi:10.1001/jama.2023.24766: <a href="https://doi.org/10.1001/jama.2023.24766" target="_blank" rel="noopener">https://doi.org/10.1001/jama.2023.24766</a></li>
        <li>Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force; Nicholson WK, Silverstein M, et al. <em>JAMA</em>. 2024;331(22):1918-1930. doi:10.1001/jama.2024.5534: <a href="https://doi.org/10.1001/jama.2024.5534" target="_blank" rel="noopener">https://doi.org/10.1001/jama.2024.5534</a></li>
<li>U.S. Preventive Services Task Force. Breast Cancer: Screening (Final Recommendation Statement, 2024).: <a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening" target="_blank" rel="noopener">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening</a></li>
        <li>USPSTF. Draft/Final modeling and evidence updates supporting biennial screening starting at age 40 (CISNET modeling publications and supporting materials).: <a href="https://www.uspreventiveservicestaskforce.org/uspstf/document/final-recommendation-statement/breast-cancer-screening" target="_blank" rel="noopener">https://www.uspreventiveservicestaskforce.org/uspstf/document/final-recommendation-statement/breast-cancer-screening</a></li>
        <li>Ho JM, et al. Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. JAMA Network Open (2022).: <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790521" target="_blank" rel="noopener">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790521</a></li>
        <li>American Cancer Society. Breast Cancer Early Detection and Diagnosis (guideline overview and high-risk MRI discussion).: <a href="https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection.html" target="_blank" rel="noopener">https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection.html</a></li>
        <li>NCI Breast Cancer Risk Assessment Tool (Gail model).: <a href="https://bcrisktool.cancer.gov/" target="_blank" rel="noopener">https://bcrisktool.cancer.gov/</a></li>
        <li>Breast Cancer Surveillance Consortium (BCSC) risk calculator.: <a href="https://tools.bcsc-scc.ucdavis.edu/BC5yearRisk/" target="_blank" rel="noopener">https://tools.bcsc-scc.ucdavis.edu/BC5yearRisk/</a></li>
        <li>CanRisk (BOADICEA / family-history and genetics–informed risk estimation tools).: <a href="https://canrisk.org/" target="_blank" rel="noopener">https://canrisk.org/</a></li>
        <li>UCSF ePrognosis Breast Cancer Screening Decision Tool (to support decisions about stopping screening).: <a href="https://eprognosis.ucsf.edu/cancer/partials/breast-cancer.php" target="_blank" rel="noopener">https://eprognosis.ucsf.edu/cancer/partials/breast-cancer.php</a></li>
        <li>Breast Cancer Prevention Partners (BCPP) – prevention and environmental health resources.: <a href="https://www.bcpp.org/" target="_blank" rel="noopener">https://www.bcpp.org/</a></li>
        <li>International Agency for Research on Cancer (IARC). Night shift work and circadian disruption as a carcinogenic hazard (classification and supporting materials).: <a href="https://www.iarc.who.int/" target="_blank" rel="noopener">https://www.iarc.who.int/</a></li>
        <li>Women’s Health Initiative (WHI) hormone therapy trials and follow-up publications (estrogen-only vs combined estrogen + progestin outcomes).: <a href="https://www.whi.org/" target="_blank" rel="noopener">https://www.whi.org/</a></li>
        <li>U.S. Food and Drug Administration (FDA). Thermography is not a substitute for mammography (safety communications).: <a href="https://www.fda.gov/medical-devices/breast-implants/thermography" target="_blank" rel="noopener">https://www.fda.gov/medical-devices/breast-implants/thermography</a></li>
        <li>National Cancer Institute. Cancer Stat Facts: Female Breast Cancer (incidence and mortality context).: <a href="https://seer.cancer.gov/statfacts/html/breast.html" target="_blank" rel="noopener">https://seer.cancer.gov/statfacts/html/breast.html</a></li>
        <li>National Academies / Endocrine Society resources on endocrine-disrupting chemicals (EDCs) and health (background context).: <a href="https://www.endocrine.org/topics/edc" target="_blank" rel="noopener">https://www.endocrine.org/topics/edc</a></li>
      </ol>

      <footer class="amh-footer">
        <div class="amh-disclaimer medical-disclaimer">
          <p><strong>Medical disclaimer:</strong> The information on this page is provided for general educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease, and it does not establish a physician–patient relationship.</p>
          <p>Do not apply this information to your specific situation without the oversight of a qualified clinician who can consider your full health history, medications, goals, preferences, and limitations. If you have urgent or severe symptoms, seek emergency care.</p>
          <p style="margin: 0;"><strong>Copyright:</strong> © Dr. Bray at Archangel Michael Health <span id="amh-year">2025</span></p>
        </div>

        <div class="amh-footer-meta">
          <span><strong>Archangel Michael Health</strong> | Internal &amp; Integrative Medicine</span>
          <span class="amh-dot">•</span>
          <span><strong>Last updated:</strong> <span id="amh-last-updated">—</span></span>
        </div>
      </footer>
    </div>
  </div>

  <!-- Image modal (click an infographic to expand) -->
  <div class="amh-img-modal" id="amhImgModal" aria-hidden="true" role="dialog" aria-label="Expanded image">
    <button class="amh-img-close" id="amhImgModalClose" type="button" aria-label="Close image">×</button>
    <img id="amhImgModalImg" alt="" />
  </div>


  <script>
    (function () {
      // ---- Last updated + year ----
      var yearEl = document.getElementById("amh-year");
      if (yearEl) {
        try { yearEl.textContent = String(new Date().getFullYear()); } catch (e) {}
      }

      var updatedEl = document.getElementById("amh-last-updated");
      if (updatedEl) {
        var lm = document.lastModified; // usually reflects server file Last-Modified (works well on GitHub Pages)
        var d = lm ? new Date(lm) : null;
        if (d && !isNaN(d.getTime())) {
          // ISO-like YYYY-MM-DD
          var yyyy = d.getFullYear();
          var mm = String(d.getMonth() + 1).padStart(2, "0");
          var dd = String(d.getDate()).padStart(2, "0");
          updatedEl.textContent = yyyy + "-" + mm + "-" + dd;
        } else {
          updatedEl.textContent = "—";
        }
      }

      // ---- TOC scrolling (support both anchor links and data-scroll buttons) ----
      function scrollToId(id) {
        var el = document.getElementById(id);
        if (!el) return;
        el.scrollIntoView({ behavior: "smooth", block: "start" });
      }

      document.addEventListener("click", function (e) {
        var btn = e.target.closest(".toc-btn[data-scroll]");
        if (btn) {
          e.preventDefault();
          scrollToId(btn.getAttribute("data-scroll"));
          return;
        }

        var link = e.target.closest('.toc a[href^="#"]');
        if (link) {
          var hash = link.getAttribute("href");
          var target = hash && hash.length > 1 ? hash.slice(1) : null;
          if (!target) return;
          e.preventDefault();
          scrollToId(target);
          history.replaceState(null, "", hash);
        }
      });

      // ---- Click-to-expand infographics ----
      var imgModal = document.getElementById("amhImgModal");
      var imgModalImg = document.getElementById("amhImgModalImg");
      var imgModalClose = document.getElementById("amhImgModalClose");

      function openImgModal(src, alt) {
        if (!imgModal || !imgModalImg) return;
        imgModalImg.src = src;
        imgModalImg.alt = alt || "";
        imgModal.classList.add("open");
        imgModal.setAttribute("aria-hidden", "false");
        document.body.classList.add("amh-modal-open");
      }

      function closeImgModal() {
        if (!imgModal || !imgModalImg) return;
        imgModal.classList.remove("open");
        imgModal.setAttribute("aria-hidden", "true");
        // Clear src after close to stop loading if user closes quickly
        imgModalImg.src = "";
        imgModalImg.alt = "";
        document.body.classList.remove("amh-modal-open");
      }

      // Make images accessible as buttons (keyboard open)
      document.querySelectorAll("img.amh-infographic").forEach(function (img) {
        img.setAttribute("role", "button");
        img.setAttribute("tabindex", "0");

        img.addEventListener("click", function () {
          openImgModal(img.currentSrc || img.src, img.alt);
        });

        img.addEventListener("keydown", function (e) {
          if (e.key === "Enter" || e.key === " ") {
            e.preventDefault();
            openImgModal(img.currentSrc || img.src, img.alt);
          }
        });
      });

      if (imgModal) {
        imgModal.addEventListener("click", function (e) {
          // Close only if user clicked the backdrop (not the image itself)
          if (e.target === imgModal) closeImgModal();
        });
      }

      if (imgModalImg) {
        imgModalImg.addEventListener("click", closeImgModal);
      }

      if (imgModalClose) {
        imgModalClose.addEventListener("click", closeImgModal);
      }

      document.addEventListener("keydown", function (e) {
        if (e.key === "Escape" && imgModal && imgModal.classList.contains("open")) {
          closeImgModal();
        }
      });



      // ---- Download PDF using html2pdf.js ----
      var btn = document.getElementById("downloadPdfBtn");
      if (!btn) return;

      function safeFilename(title) {
        return (title || "patient-guide")
          .toLowerCase()
          .replace(/[^a-z0-9]+/g, "-")
          .replace(/(^-|-$)/g, "");
      }

      btn.addEventListener("click", function () {
        if (typeof html2pdf === "undefined") {
          alert("PDF generator is still loading. Please try again in a moment, or use Print / Save as PDF.");
          return;
        }

        btn.disabled = true;
        btn.textContent = "Preparing PDF...";

        var title = (document.getElementById("page-title") && document.getElementById("page-title").textContent) || "Patient Guide";
        var filename = safeFilename(title) + ".pdf";

        // Clone content for PDF and remove UI elements
        var source = document.getElementById("pdf-root").cloneNode(true);
        source.querySelectorAll(".no-print").forEach(function (el) { el.remove(); });

        var wrapper = document.createElement("div");
        wrapper.style.background = "#ffffff";
        wrapper.appendChild(source);

        var opt = {
          margin: [0.5, 0.5, 0.6, 0.5], // inches
          filename: filename,
          image: { type: "jpeg", quality: 0.98 },
          html2canvas: { scale: 2, useCORS: true, letterRendering: true },
          jsPDF: { unit: "in", format: "letter", orientation: "portrait" },
          pagebreak: { mode: ["css", "legacy"] }
        };

        html2pdf()
          .set(opt)
          .from(wrapper)
          .save()
          .catch(function (err) {
            console.error(err);
            alert("Could not generate the PDF in this browser. Please use Print / Save as PDF.");
          })
          .finally(function () {
            btn.disabled = false;
            btn.textContent = "Download PDF";
          });
      });
    })();
  </script>
</body>
</html>
